A61K 40/4236
Chemokines
Official title: {Chemokines}
A61K40/4236 (Chemokines) appears on 16 US grants and 38 published applications in this corpus.
Search patents in A61K- Granted patents
- 16
- Published applications
- 38
- Assignees
- 30
- Inventors
- 86
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 1 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 1 | 1 |
| 2017 | 0 | 1 |
| 2018 | 1 | 3 |
| 2019 | 1 | 3 |
| 2020 | 0 | 0 |
| 2021 | 3 | 8 |
| 2022 | 2 | 6 |
| 2023 | 1 | 3 |
| 2024 | 2 | 4 |
| 2025 | 2 | 5 |
| 2026 | 3 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Combination immunotherapy15 Sep 2026US 12,735,466 B2The Regents of the University of California
- Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof17 Feb 2026US 12,551,543 B2IO Biotech ApS
- Chemokine responsive activated natural killer cells with secondary homing activation for verified targets3 Feb 2026US 12,540,170 B2ImmunityBio, Inc.
- Vaccine compositions comprising C-C motif chemokine 22 (CCL22) or fragments thereof16 Dec 2025US 12,496,333 B2IO Biotech ApS
- Methods for predicting outcomes and treating colorectal cancer using a cell atlas23 Sep 2025US 12,421,557 B2Massachusetts Institute of Technology
- Cxcr3 overexpression in car-nk cells primes migration/homing into the tumor microenvironment2 Jul 2026US 2026/0183396 A1Dana-Farber Cancer Institute, Inc.
- Chemokine responsive activated natural killer cells with secondary homing activation for verified targets21 May 2026US 2026/0139034 A1ImmunityBio, Inc.
- Chimeric antigen receptor, cell expressing said receptor, pharmaceutical composition including said cell, method for producing said cell, and polynucleotide or vector including nucleotide sequence encoding said chimeric antigen receptor30 Oct 2025US 2025/0332195 A1Noile-Immune Biotech, Inc.
- Compositions and methods for maintaining a ccl3/ccl4 and ccr5 interaction program expressed during tumor progression23 Oct 2025US 2025/0325588 A1The Brigham and Women S Hospital, Inc.
- Isolated immune cell expressing a receptor, interleukin-7, and chemokine (c-c motif) ligand 1928 Aug 2025US 2025/0268942 A1Noile-Immune Biotech, Inc.
Most cited
By later US patents
- Tetanus toxoid and CCL3 improve DC vaccines8US 9,974,848 B2Duke University · 2018
- Car expression vector and car-expressing T cells2US 10,316,102 B2Yamaguchi University · 2019
- Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof2US 11,298,413 B2IO Biotech ApS · 2022
- Creating bioengineered lymph nodes2US 9,234,175 B2H. Lee Moffitt Cancer Center and Research Institute, Inc. · 2016
- CAR expression vector and CAR-expressing T cells1US 10,906,984 B2Yamaguchi University · 2021